Mangoceuticals Inc

Mangoceuticals Inc(MGRX)股票分析

$0.200

+0.009 (+4.28%)收盤時

Loading chart…
最高
0.209
開盤
0.192
成交量加權均價
0.20
成交量
319.40K
市值
9.35M
最低
0.186
成交金額
63.39K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin.

AI 分析 of Mangoceuticals Inc (MGRX)

賣出

Mangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.

估值指標

Mangoceuticals Inc(MGRX)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 MGRX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MGRX

$1.71

情境價格

基

基準

基準 · 50%MGRX

$1.48

情境價格

悲

悲觀

悲觀 · 25%MGRX

$1.39

情境價格

事件時間軸

2026-10-01 (ET)

16:00:00

Mangoceuticals' Former Subsidiary Secures $2.5M Investment

2026-07-30 (ET)

09:30:00

Mangoceuticals Enters Business Combination Agreement with Nuclea Energy

2026-03-17 (ET)

16:20:00

Mangoceuticals Sues Clarity Ventures for Over $73M

2026-01-13 (ET)

17:40:00

Mangoceuticals Files to Sell 2.64M Shares of Common Stock

2025-12-19 (ET)

07:40:00

Mangoceuticals Partners with Cube Group for Up to $100M Solana Digital Asset Strategy

資訊

MGRX 常見問題 —— 由 Alphio AI 解答

Mangoceuticals, Inc. is focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx and is also focused on wellness solutions. It is advancing its proprietary antiviral compound MGX-0024. The Company offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. It has developed and is commercially marketing a brand of ED products under the brand name Mango; a brand of hair loss products under the brand name Grow; a brand of hormone balance and therapy products under the name Mojo, and a brand of weight loss products under the brand name Slim. Prime by MangoRx is a TRT product available by prescription. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Mangoceuticals Inc is not a good buy right now due to its extremely low RSI of 18.24, indicating oversold conditions, and a staggering year-to-date change of -76.56%.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易